Andy Chen
Stock Analyst at Wolfe Research
(2.25)
# 2,659
Out of 4,893 analysts
39
Total ratings
44.44%
Success rate
-0.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Initiates: Outperform | $170 | $104.77 | +62.26% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $45.98 | +6.57% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $19.37 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $31.27 | +75.89% | 1 | Jun 17, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Peer Perform | n/a | $128.55 | - | 1 | Jun 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $48.28 | +26.35% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $12.13 | +73.12% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $25.74 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $32.33 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $10.57 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $14.23 | +40.55% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $24.21 | +102.40% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $10.49 | +81.12% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $17.29 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $555.19 | +25.54% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $320.87 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.72 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.46 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $45.18 | +43.87% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $51.13 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $308.59 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.04 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.44 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $42.83 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $60.08 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.22 | +51.52% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $478.97 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $96.47 | -56.46% | 1 | Feb 15, 2024 |
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $104.77
Upside: +62.26%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $45.98
Upside: +6.57%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.37
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $31.27
Upside: +75.89%
Blueprint Medicines
Jun 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $128.55
Upside: -
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $48.28
Upside: +26.35%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $12.13
Upside: +73.12%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $25.74
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $32.33
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $10.57
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $14.23
Upside: +40.55%
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $24.21
Upside: +102.40%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $10.49
Upside: +81.12%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $17.29
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $555.19
Upside: +25.54%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $320.87
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $68.72
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $22.46
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $45.18
Upside: +43.87%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $51.13
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $308.59
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.04
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.44
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $42.83
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $60.08
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.22
Upside: +51.52%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $478.97
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $96.47
Upside: -56.46%